Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective.

Shigeaki SuzukiAkiyuki UzawaHiroyuki Murai

Published in: Expert review of clinical immunology (2022)

Efgartigimod is a promising biological drug for patients with moderate to severe generalized MG with or without anti-acetylcholine receptor antibodies in Japan.

Keyphrases

myasthenia gravis
early onset
high intensity
emergency department